In the absence of a reliable biomarker capable of directly demonstrating the removal of TDP‐43 from the brain, clinical trials of potential disease‐modifying therapies in FTLD and ALS have relied on indirect measures, such as brain volumetry and indices of microstructural integrity. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.